
Opinion|Videos|October 14, 2026
Treatment Sequencing and Closing Remarks
Explore how neoadjuvant therapy guides TGCT surgery timing, side-effect tradeoffs, and team-based decision-making for locally advanced disease without rushing into operations.
Advertisement
Panelists then proceed to discuss treatment sequencing and the patients they see in real practice compared to clinical trials. One panelist delves into his understanding and opinions on neoadjuvant care in his practice setting. The panelists then proceed to discuss their takeaways from their discussion during this program. They emphasize the importance of a multidisciplinary team and the patient’s experience. The panelists provide closing remarks and finish the conversation.
Advertisement
Related to this article

Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.

First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.

Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.

Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma
2
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
3
CDK4/6 Inhibitors Anchor First-Line Metastatic Breast Cancer Care, But Oral SERDs May Fall Short
4
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
5




